Tandem Diabetes Care, Inc. (TNDM) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 253.00M USD | Liabilities, Current |
| Cash and equivalents | 62.82M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 162.06M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 135.11M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $253.00M | $62.82M | (m) | $162.06M | $135.11M | (m) |
| 2026-03-31 | (m) | $247.96M | $179.32M | (m) | $140.67M | $126.40M | (m) |
| 2025-12-31 | (m) | $242.72M | $90.63M | (m) | $165.49M | $128.77M | (m) |
| 2025-09-30 | (m) | $252.54M | $91.95M | (m) | $125.94M | $137.28M | (m) |
| 2025-06-30 | (m) | $251.69M | $64.11M | (m) | $128.44M | $142.57M | (m) |
| 2025-03-31 | (m) | $288.18M | $53.57M | (m) | $126.56M | $141.16M | (m) |
| 2024-12-31 | (m) | $247.05M | $69.23M | (m) | $114.58M | $149.61M | (m) |
| 2024-09-30 | (m) | $259.28M | $49.04M | (m) | $107.19M | $152.44M | (m) |
| 2024-06-30 | (m) | $240.61M | $47.70M | (m) | $98.12M | $161.66M | (m) |
| 2024-03-31 | (m) | $192.97M | $58.98M | (m) | $92.97M | $153.89M | (m) |
| 2023-12-31 | (m) | $195.26M | $58.87M | (m) | $105.56M | $157.94M | (m) |
| 2023-09-30 | (m) | $187.11M | $79.61M | (m) | $100.32M | $143.49M | (m) |
| 2023-06-30 | (m) | $174.66M | $130.75M | (m) | $98.71M | $147.60M | (m) |
| 2023-03-31 | (m) | $171.16M | $127.76M | (m) | $91.39M | $131.56M | (m) |
| 2022-12-31 | (m) | $165.29M | $172.52M | (m) | $114.72M | $111.12M | (m) |
| 2022-09-30 | (m) | $173.63M | $123.79M | (m) | $112.81M | $104.77M | (m) |
| 2022-06-30 | (m) | $139.26M | $114.97M | (m) | $103.76M | $88.10M | (m) |
| 2022-03-31 | (m) | $131.81M | $93.68M | (m) | $94.13M | $79.99M | (m) |
| 2021-12-31 | (m) | $131.86M | $71.18M | (m) | $110.72M | $68.55M | (m) |
| 2021-09-30 | (m) | $119.65M | $112.38M | (m) | $87.46M | $65.73M | (m) |
| 2021-06-30 | (m) | $108.72M | $98.58M | (m) | $80.21M | $66.70M | (m) |
| 2021-03-31 | (m) | $103.41M | $120.79M | (m) | $73.67M | $66.82M | (m) |
| 2020-12-31 | (m) | $103.85M | $94.61M | (m) | $82.19M | $63.72M | (m) |
| 2020-09-30 | (m) | $105.51M | $129.48M | (m) | $52.10M | $70.64M | (m) |
| 2020-06-30 | (m) | $114.31M | $222.48M | (m) | $45.03M | $62.26M | (m) |
| 2020-03-31 | (m) | $99.65M | $74.48M | (m) | $53.96M | $60.47M | (m) |
| 2019-12-31 | $223.04M | $99.40M | $51.17M | $125.28M | $46.59M | $49.07M | 2.24× |
| 2019-09-30 | $202.27M | $100.27M | $46.06M | $110.89M | $45.33M | $40.73M | 2.02× |
| 2019-06-30 | (m) | $84.21M | $38.16M | (m) | $48.44M | $27.34M | (m) |
| 2019-03-31 | (m) | $76.68M | $40.45M | (m) | $33.03M | $22.83M | (m) |
| 2018-12-31 | (m) | $66.29M | $41.83M | (m) | $35.19M | $19.90M | (m) |
| 2018-09-30 | (m) | $58.55M | $32.33M | (m) | $21.69M | $24.37M | (m) |
| 2018-06-30 | (m) | $42.51M | $50.55M | (m) | $13.91M | $24.91M | (m) |
| 2018-03-31 | (m) | $43.71M | $62.58M | (m) | $13.04M | $26.49M | (m) |
| 2017-12-31 | (m) | $36.09M | $13.70M | (m) | $20.79M | $26.99M | (m) |
| 2017-09-30 | (m) | $29.41M | $12.08M | (m) | $10.58M | $29.98M | (m) |
| 2017-06-30 | (m) | $30.84M | $27.35M | (m) | $9.03M | $25.82M | (m) |
| 2017-03-31 | (m) | $29.21M | $40.33M | (m) | $7.69M | $23.75M | (m) |
| 2016-12-31 | (m) | $31.48M | $44.68M | (m) | $11.17M | $21.20M | (m) |
| 2016-09-30 | (m) | $34.82M | $17.96M | (m) | $8.20M | $22.90M | (m) |
| 2016-06-30 | (m) | $27.07M | $30.25M | (m) | $9.43M | $21.69M | (m) |
| 2016-03-31 | (m) | $24.82M | $40.61M | (m) | $9.09M | $20.20M | (m) |
| 2015-12-31 | (m) | $26.52M | $43.09M | (m) | $14.05M | $17.54M | (m) |
| 2015-09-30 | (m) | $22.32M | $43.20M | (m) | $7.01M | $17.55M | (m) |
| 2015-06-30 | (m) | $18.48M | $45.92M | (m) | $7.47M | $14.67M | (m) |
| 2015-03-31 | (m) | $18.77M | $62.55M | (m) | $5.23M | $13.58M | (m) |
| 2014-12-31 | (m) | $18.09M | $31.18M | (m) | $7.65M | $11.91M | (m) |
| 2014-09-30 | (m) | $15.66M | $35.56M | (m) | $5.84M | $11.89M | (m) |
| 2014-06-30 | (m) | $13.21M | $64.21M | (m) | $4.36M | $11.12M | (m) |
| 2014-03-31 | (m) | $13.14M | $76.83M | (m) | $3.42M | $10.16M | (m) |
| 2013-12-31 | (m) | $14.60M | $124.39M | (m) | $5.30M | $10.33M | (m) |
| 2013-09-30 | (m) | (m) | $15.55M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $30.13M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $29.44M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $17.16M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $8.66M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |